l General Information |
Product Name | Thalidomide |
General description | Thalidomide is a piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action. |
Synonym | (±)-2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione |
Purity | ≥99%(HPLC) | CAS Number | 50-35-1 |
Formula | C13H10N2O4 | Molecular Weight | 258.23 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White or Off-white solid |
Solubility(25℃) | DMSO | ≥50mg/mL |
Ethanol | ~2mg/mL |
Water | insoluble |
l Biological Information |
Biochem/Physiol Actions | Thalidomide is an immunomodulatory agent with a spectrum of activity that is not fully characterized. Thalidomide is racemic — it contains both left and right handed isomers in equal amounts: one enantiomer is effective against morning sickness, and the other is teratogenic. The enantiomers are converted to each other in vivo. That is, if a human is given D-thalidomide or L-thalidomide, both isomers can be found in the serum. Hence, administering only one enantiomer will not prevent the teratogenic effect in humans. |
Application | 1. Leprostatic Agents Substances that suppress Mycobacterium leprae, ameliorate the clinical manifestations of leprosy, and/or reduce the incidence and severity of leprous reactions. 2. Teratogens An agent that causes the production of physical defects in the developing embryo. 3. Angiogenesis Inhibitors Agents and endogenous substances that antagonize or inhibit the development of new blood vessels. |
l Packaging & Storage |
Packaging | 250mg; 1g |
Storage temp. | 0-5℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
